Jones Keith Anthony 4

What Happened

• Keith Anthony Jones, a director of Humacyte, received a grant/award of 80,000 derivative shares (transaction code A) on June 11, 2026. The filing reports an acquisition price of $0.00 for the award (derivative instrument), so no cash value is shown in the Form 4.

Key Details

• Transaction date: June 11, 2026; Filing date: June 12, 2026 (timely).
• Instrument: Award/grant of derivative securities for 80,000 shares; reported price $0.00.
• Vesting/exercisability (footnote F1): First 25% becomes exercisable on June 11, 2027; thereafter 1/48 of the option becomes exercisable on the 11th of each month through June 11, 2030.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Filing status: Not indicated as late.

Context

• This was an equity award to a company director (not an open-market buy or a sale). The award vests over time per the schedule above; it appears to be a standard time-based vesting arrangement. Because the filing reports a $0.00 acquisition price for the derivative, any market value depends on Humacyte’s stock price and the specific terms of the derivative (option vs. RSU), which are not fully detailed in the excerpt.